Wilder-Smith C, Schimke J, Vergin H, Senn H J
Haematology/Oncology Unit, Department of Medicine C, Kantonsspital, Nuremberg, Fed. Rep. of Germany.
Arzneimittelforschung. 1989 Nov;39(11):1464-7.
Delayed nausea and emesis are common after cancer chemotherapy, especially cisplatin-containing regimens. Often no, or inadequate, prophylactic antiemetic cover is prescribed in these usually ambulant patients. Metoclopramide is a very effective drug in preventing the acute emetic and nauseating effects of cisplatin. The long-acting metoclopramide formulations (in the present study: Gastrosil retard) may be effective in preventing the delayed toxicity. 12-hourly dosing of 60 mg long-acting metoclopramide in a typical oncology ward situation led to stable metoclopramide levels of approximately 100ng/ml in the observed 74 h in 18 patients, with the well-known wide plasma concentration variability. The clinical efficacy of long-acting metoclopramide in this indication remains to be evaluated.
延迟性恶心和呕吐在癌症化疗后很常见,尤其是含顺铂的化疗方案。在这些通常可走动的患者中,往往未开具预防性止吐药物,或开具的药物不足。甲氧氯普胺是预防顺铂急性呕吐和恶心作用的非常有效的药物。长效甲氧氯普胺制剂(在本研究中:胃复安缓释片)可能对预防延迟性毒性有效。在典型的肿瘤病房环境中,对18名患者每12小时给予60毫克长效甲氧氯普胺,在观察的74小时内,甲氧氯普胺水平稳定在约100纳克/毫升,血浆浓度存在众所周知的广泛变异性。长效甲氧氯普胺在此适应症中的临床疗效仍有待评估。